ClinicalTrials.gg
Active, not recruitingNCT06205368CombineAppUpdated Oct 30, 2026

Evaluating the Effectiveness of a Mobile HIV Prevention App to Increase HIV and Sexually Transmitted Infections (STI) Testing and PrEP Initiation Among Rural Men Who Have Sex With Men

An interventional study of Combine mobile app and Motivational interview in HIV Infections, STI and HIV Pre-exposure Prophylaxis, sponsored by Emory University. Active, not recruiting at 1 site in United States. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Emory University · Not applicable, Interventional, and Prevention

How we know

Updated Oct 30, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
473
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 19 studies in HIV Infections by Emory University — 4 open to participants now, 6 under way, none of them phase 3. HIV Infections · Emory University.

Enrollment
5th of 17
473 · median 63
Started
2024
the only one that year
No phase
9 of 19
3 open now
Registered
15th of 19
by date

Among the 19 studies in HIV Infections by Emory University, this one is the 5th largest by enrollment of the 17 interventional ones that give a count, is the only one that started in 2024, is one of 9 with no phase, and was the 15th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

4 of the 19 studies in HIV Infections by Emory University are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 45 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in HIV Infections by Emory University, or all of them as a file.
02

Study summary

The goal of this clinical trial is to test the efficacy of a mobile app, Combine, to increase the uptake of HIV and STI testing and pre-exposure prophylaxis (PrEP) over 24 months and to assess the effects of different implementation strategies on intervention maintenance among GBMSM in rural southern United States. The main aims of the study are:

  • To assess the relative effects of three treatment conditions on gains in engagement in HIV prevention compared to a modified standard of care control condition
  • Measure and assess secondary factors affecting app implementation
  • Refine implementation strategies and coordinate with potential funders Participants will download an HIV prevention smartphone app and be randomly assigned to one of four groups:
  • Control: App access only
  • Self-testing: App access + ability to order HIV and STI self-test kits
  • Motivational interview: App access + motivational interview to develop plans to use app effectively.
  • Self-testing + motivational interview: App access + ability to order HIV and STI self-test kits + motivational interview to develop plans to use app effectively.

Researchers will compare each of the latter three groups to the control condition to see if HIV and STI testing increase in these groups

Read the detailed description

The uptake of HIV and STI testing among gay and bisexual men who have sex with men (GBMSM) in the rural southern US is low. However, HIV and STI testing is a fundamental gateway to preventive services, such as PrEP, and treatment provision. Thus, the research team must identify methods to increase the uptake of HIV and STI testing among this population that experiences disproportionate HIV and STI incidence. The research team has developed an app, Combine, that is an adaptation of HealthMindr, an app that has demonstrated efficacy in increasing the uptake of HIV testing among urban GBMSM. Combine was adapted using input from GBMSM in rural areas to address issues specific to this population such as increased experiences of stigma and reduced access to culturally competent care. The investigator proposes to conduct a Type 2 Hybrid Effectiveness-Implementation randomized controlled trial to test the efficacy of Combine to increase uptake of HIV and STI testing over 24 months of follow-up and to examine the effect of different implementation strategies among GBMSM in the rural South. Combine will include components for self-administered risk assessments, developing and supporting a plan for frequent HIV and STI testing, information about PrEP, and PrEP and HIV/STI testing provider locators. Previous trials of app-based HIV prevention have included the ability to order free HIV and STI self-test kits. However, there is no consensus among health officials around whether at-home self-tests are an optimal solution for increasing HIV and STI testing. Additionally, despite the availability of free HIV and STI self-test kits in previous studies, large proportions of men still do not complete HIV tests, and even fewer complete STI tests. Thus, the investigator will evaluate the effect of two different intervention components on HIV and STI uptake in a 2x2 factorial trial design: availability of HIV and STI self-test kits ordered through the app and a motivational interview designed to enhance the existing app content, increased self-efficacy to develop and follow through with a testing plan, and develop strategies to deal with experiences of stigma.

The investigator will assess the main effects of the availability of HIV and STI self-test kits and the motivational interview on HIV and STI testing uptake, PrEP initiation, and intervention maintenance over 24 months of follow-up. The investigator's community-based partner, Engaging Arkansas Communities, will work with the research team through all stages of the project to ensure that the team is obtaining the necessary data to inform future implementation.

03

Conditions studied

  • HIV Infections
  • STI
  • HIV Pre-exposure Prophylaxis

Keywords

  • GBMSM
  • PrEP
  • HIV
  • Gay
  • HIV prevention
  • STI testing
  • HIV testing
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Assigned male at birth and currently identifies as male
  • Age 18-45 years, inclusive
  • Reside in the U.S. South as defined by the Census Bureau or in Missouri
  • Reside in a county classified as rural using the Index of Relative Rurality
  • Have an Android or iPhone operating system (iOS) phone with active service
  • Willing to download a study app to their phone
  • English speaker
  • Report anal sex with a man in the past 12 months
  • -negative or unknown serostatus
  • Not currently using PrEP

Exclusion criteria

Exclusion criteria

- Unable to provide consent

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Factorial assignment
Masking
None (open label)
Enrollment
473 participants (actual)

Study arms

  • Other
    Combine app with all features except the ability to order self-test kits

    Participants will receive a modified standard of care which consists of the Combine app with all features except the ability to order self-test kits. The HIV/STI testing locator in the app will be available.

    Behavioral: Combine mobile app

  • Other
    Combine app + motivational interview

    In addition to the other Combine app features, participants will receive a motivational interview within 4 weeks of downloading the app.

    Behavioral: Combine mobile app · Behavioral: Motivational interview

  • Other
    Combine app + ability to order up 2 free HIV/STI self-test kits

    In addition to the other Combine app features, participants in this arm will be able to order up to two HIV/STI self-test kits at no charge during each year of follow-up.

    Behavioral: Combine mobile app · Behavioral: HIV/STI testing

  • Other
    Combine app + motivational interview + ability to order HIV/STI test kits via the app

    In addition to the other Combine app features, participants in this arm will receive both the motivational interview and the ability to order HIV/STI test kits via the app.

    Behavioral: Combine mobile app · Behavioral: Motivational interview · Behavioral: HIV/STI testing

Interventions

  • BehavioralCombine mobile app

    * HIV/STI testing: learn more about testing options; create a plan to test 1-4 times in the coming year; locate places for those tests and/or order at-home test kits; and schedule reminders for periodic testing * Pre-exposure prophylaxis: PrEP self-assessment at first app use; monthly rescreening for PrEP eligibility; recommendation for PrEP based on Centers for Disease Control and Prevention (CDC) criteria; PrEP provider locator. * Behavioral risk assessment: e.g. HIV risk behaviors; sex while drunk or high, condomless anal intercourse with a positive or unknown HIV status partner, multiple sex partners, recent STI diagnosis, use of drugs) and protective behaviors * Non-occupational post-exposure prophylaxis (nPEP): information about nPEP; self-assessment; locator; referral to PrEP for men who evaluate multiple exposures for nPEP indication * Product ordering: participants can order condoms, condom-compatible lubricants, and at-home STI specimen collection kits.

    Also known as: Mobile app

  • BehavioralMotivational interview

    The interview will be grounded in the Social Cognitive Theory of self-regulation (SCT) to reflect the underlying theory of the Combine app. It will be designed to enhance the effectiveness of the app by highlighting app features (e.g., frequently asked questions, product ordering, testing locators) and discussing strategies for following through on goals related to sexual health (e.g., creating and adhering to a testing plan)

  • BehavioralHIV/STI testing

    Participants will be able to order free HIV/STI self-test kits; they will be able to order up to two sets of kits during each of years 1 and 2 of follow-up. HIV and STI test kit orders are independent: ordering an HIV test kit does not trigger shipment of an STI kit and vice versa. When an order is placed, kits containing biospecimen self-collection tools are shipped directly to the participant along with written instructions and a link to video instructions on how to collect each of the samples (e.g., urine, rectal, blood). Return packaging is enclosed with instructions for participants to locate a drop-off location to return their samples to the lab.

06

What researchers measure

Primary outcomes

  1. Uptake of HIV testing

    The investigator will look at the change in number of participants getting tested for HIV by using online surveys. Uptake of testing will be defined as ordering, using, and returning a kit for laboratory analysis or obtaining a test at an in-person provider and reporting the result.

    Time frame: Screening, Month 6, Month 12, Month 18, Month 24

  2. Uptake of STI testing

    The investigator will look at the change in number of participants getting tested for STIs by using online surveys. Uptake of testing will be defined as ordering, using, and returning a kit for laboratory analysis or obtaining a test at an in-person provider and reporting the result.

    Time frame: Screening, Month 6, Month 12, Month 18, Month 24

  3. PrEP initiation

    The investigator will look at the change in number of participants taking PrEP over the course of the study. PrEP initiation will be defined as obtaining a new PrEP prescription for the first time or after a period of non-use of at least three months

    Time frame: Screening, Month 6, Month 12, Month 18, Month 24

07

Study locations

1 site
08

References and documents

Publications

  • Jones J, Manley G, Glynn TR, Wall KM, Baral SD, Harris ED, Benkeser D, Sullivan PS. Evaluating the Effectiveness of a Mobile HIV Prevention App to Increase HIV and Sexually Transmitted Infection Testing and Pre-Exposure Prophylaxis Initiation Among Rural Men Who Have Sex With Men in the Southern United States: Protocol for a Randomized Controlled Trial. JMIR Res Protoc. 2025 Jul 23;14:e69540. doi: 10.2196/69540. PubMed 40699887 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Demographics and Primary Outcomes data will be shared upon request.

Supporting information: Study protocol, Statistical analysis plan

Time frame: After the publication of primary outcome data

Access criteria: Analyses that don't overlap with specific aims, per PI approval will be shared with those who request them from the PI via email.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Sep 2027, 42 months after the start.

Of 393 non-industry interventional studies with no phase under HIV Infections, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 45. This study's planned 42 months is above that.

Counting every sponsor, half of 402 studies reached it within 28 months; a quarter within 16 and three quarters within 45.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 30, 2026: primary completion Aug 2027 → Sep 2027 and completion Aug 2027 → Sep 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 4, 2024
First posted
Jan 16, 2024
StartActual
Mar 27, 2024
Primary completionEst.
Sep 2027was Aug 2027
CompletionEst.
Sep 2027was Aug 2027
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Aug 2027→Sep 2027
Oct 30, 2026
Study completion
Aug 2027→Sep 2027
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Primary completion Aug 2027→Sep 2027
    Study completion Aug 2027→Sep 2027
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06205368
Lead sponsor
Emory University
Responsible party
Jeb Jones (Professor, Emory University) — Principal investigator
First posted
Jan 16, 2024
Start date
Mar 27, 2024
Primary completion
Sep 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Oct 30, 2026

Study contacts

Jeb Jones, PhD
principal investigator · Rollins School of Public Health

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion